JP2024540152A - 抗ctla-4抗体投与レジメン - Google Patents
抗ctla-4抗体投与レジメン Download PDFInfo
- Publication number
- JP2024540152A JP2024540152A JP2024525557A JP2024525557A JP2024540152A JP 2024540152 A JP2024540152 A JP 2024540152A JP 2024525557 A JP2024525557 A JP 2024525557A JP 2024525557 A JP2024525557 A JP 2024525557A JP 2024540152 A JP2024540152 A JP 2024540152A
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- ctla
- antibody
- seq
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163273660P | 2021-10-29 | 2021-10-29 | |
| US63/273,660 | 2021-10-29 | ||
| PCT/US2022/078875 WO2023077069A1 (en) | 2021-10-29 | 2022-10-28 | Anti-ctla-4 antibody dosing regimens |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024540152A true JP2024540152A (ja) | 2024-10-31 |
| JP2024540152A5 JP2024540152A5 (cg-RX-API-DMAC7.html) | 2025-11-07 |
Family
ID=86158833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024525557A Pending JP2024540152A (ja) | 2021-10-29 | 2022-10-28 | 抗ctla-4抗体投与レジメン |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20260139052A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4422685A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024540152A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240099187A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118176021A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022377644A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3234351A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024004429A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202325738A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023077069A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024238912A1 (en) * | 2023-05-17 | 2024-11-21 | OncoC4, Inc. | Ph-sensitive anti-ctla-4 antibodies and uses thereof |
| WO2026041780A2 (en) * | 2024-08-23 | 2026-02-26 | BioNTech SE | Combination therapy comprising anti-ctla4 antibodies and chemotherapy for cancer treatment |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ568016A (en) * | 2005-12-07 | 2011-12-22 | Medarex Inc | CTLA-4 antibody dosage escalation regimens |
| EP2912063A1 (en) * | 2012-10-23 | 2015-09-02 | Bristol-Myers Squibb Company | Combination of anti-kir and anti-ctla-4 antibodies to treat cancer |
| LT3142751T (lt) * | 2014-05-13 | 2019-09-25 | Medimmune Limited | Anti-b7-h1 ir anti-ctla-4 antikūnai nesmulkialąstelinio plaučių vėžio gydymui |
| AU2016370648B2 (en) | 2015-12-15 | 2023-03-09 | OncoC4, Inc. | Chimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereof |
| TWI799432B (zh) * | 2017-07-27 | 2023-04-21 | 美商再生元醫藥公司 | 抗ctla-4抗體及其用途 |
| CN119792515A (zh) * | 2018-02-13 | 2025-04-11 | 默沙东有限责任公司 | 用抗pd-1抗体和抗ctla-4抗体治疗癌症的方法 |
-
2022
- 2022-10-28 MX MX2024004429A patent/MX2024004429A/es unknown
- 2022-10-28 JP JP2024525557A patent/JP2024540152A/ja active Pending
- 2022-10-28 CN CN202280072636.XA patent/CN118176021A/zh active Pending
- 2022-10-28 US US18/705,924 patent/US20260139052A1/en active Pending
- 2022-10-28 AU AU2022377644A patent/AU2022377644A1/en active Pending
- 2022-10-28 WO PCT/US2022/078875 patent/WO2023077069A1/en not_active Ceased
- 2022-10-28 CA CA3234351A patent/CA3234351A1/en active Pending
- 2022-10-28 EP EP22888534.9A patent/EP4422685A4/en active Pending
- 2022-10-28 TW TW111141150A patent/TW202325738A/zh unknown
- 2022-10-28 KR KR1020247012748A patent/KR20240099187A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4422685A1 (en) | 2024-09-04 |
| TW202325738A (zh) | 2023-07-01 |
| WO2023077069A1 (en) | 2023-05-04 |
| AU2022377644A1 (en) | 2024-05-16 |
| US20260139052A1 (en) | 2026-05-21 |
| EP4422685A4 (en) | 2025-12-03 |
| KR20240099187A (ko) | 2024-06-28 |
| CN118176021A (zh) | 2024-06-11 |
| CA3234351A1 (en) | 2023-05-04 |
| MX2024004429A (es) | 2024-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7519477B2 (ja) | 非小細胞肺がんを治療するための抗b7-h1および抗ctla-4抗体 | |
| AU2021221560B2 (en) | Use of glutamate modulating agents with immunotherapies to treat cancer | |
| ES2951650T3 (es) | Uso de un anticuerpo anti-PD-1 junto con un anticuerpo anti-CD30 en el tratamiento del linfoma | |
| WO2017087280A1 (en) | Methods of treating her2-positive cancer | |
| US12565528B2 (en) | LAG-3 antagonist therapy for lung cancer | |
| US20260092112A1 (en) | Use of anti-ctla-4 antibodies for treating adenoid cystic carcinoma | |
| JP2022184998A (ja) | 特定の癌の治療のためのラムシルマブとペンブロリズマブとの組み合わせ | |
| JP2023011902A (ja) | Pd-1阻害剤を投与することにより子宮頸がんを処置する方法 | |
| US20260139052A1 (en) | Anti-ctla-4 antibody dosing regimens | |
| EP4469477A1 (en) | Combination therapy for hepatocellular carcinoma | |
| HK40106641A (en) | Anti-ctla-4 antibody dosing regimens | |
| TW202517679A (zh) | 以抗ilt2抗體治療癌症 | |
| HK40006436B (en) | Use of glutamate modulating agents with immunotherapies to treat cancer | |
| HK40006436A (en) | Use of glutamate modulating agents with immunotherapies to treat cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251028 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20251028 |